Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.The company also noted a cash position of $85.2 million as of December 31, 2025, which it expects to sustain operations into the second half of 2028.Tumultuous 2025 For KorroChardan Research wrote that 2025 was a tumultuous year for Korro.After building momentum from June to October, the company suffered a considerable setback i ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Elong Power Holding Limited (ELPW) is up 57% at $5.65 - Citizens, Inc. (CIA) is up 17% at $5.78 - The Oncology Institute, Inc. (TOI) is up 17% at $3.08 - Everbright Digital Holding Limited (EDHL) is up 12% at $3.89 - Universal Electronics Inc. (UEIC) is up 10% at $4.06 - Korro Bio, Inc. (KRRO) is up 9% at $12.57 - Silvaco Group, Inc. (SVCO) is up 9% at $3.60 - Clene Inc. (CLNN) is up 7% at $6.38 - AleAnna, Inc. (ANNA) is up 7% at $3.91 - Klarna Group plc (KLAR) is up 5% at $15.40 [3] Premarket Losers - KinderCare Learning Companies, Inc. (KLC) is down 32% at $2.30 - PAR Technology Corporation (PAR) is down 23% at $12.22 - EverCommerce Inc. (EVCM) is down 23% at $9.25 - SenesTech, Inc. (SNES) is down 21% at $1.78 - Once Upon A Farm, PBC (OFRM) is down 18% at $16.60 - PagerDuty, Inc. (PD) is down 12% at $6.35 - SciSparc Ltd. (SPRC) is down 10% at $4.25 - Agape ATP Corporation (ATPC) is down 9% at $5.09 - OIO Group (OIO) is down 9% at $3.28 - Lifetime Brands, Inc. (LCUT) is down 6% at $3.24 [4]

Core Insights - Korro Bio, Inc. reported a quarterly loss of $5.32 per share, significantly worse than the Zacks Consensus Estimate of a loss of $1.93, marking an earnings surprise of -175.08% [1] - The company's revenues for the quarter were $1.29 million, missing the Zacks Consensus Estimate by 13.87%, and down from $2.27 million a year ago [2] - Korro Bio's stock has increased by approximately 46.8% since the beginning of the year, contrasting with a 1% decline in the S&P 500 [3] Financial Performance - Over the last four quarters, Korro Bio has surpassed consensus EPS estimates two times, but has not beaten revenue estimates during the same period [2] - The current consensus EPS estimate for the upcoming quarter is -$1.86 on revenues of $1.5 million, and for the current fiscal year, it is -$7.01 on revenues of $6 million [7] Market Outlook - The company's earnings outlook is crucial for assessing future stock performance, with recent estimate revisions trending unfavorably, resulting in a Zacks Rank 4 (Sell) [6] - The Medical - Drugs industry, to which Korro Bio belongs, is currently in the top 35% of Zacks industries, indicating a favorable industry outlook [8]

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-39062 Korro Bio, Inc. (Exact name of registrant as specified in its chart ...

Core Insights - Korro Bio, Inc. is focused on developing RNA editing-based genetic medicines for rare and prevalent diseases, reporting significant progress in its clinical development and financial position for the year ending December 31, 2025 [1][2]. Financial Performance - As of December 31, 2025, Korro reported cash, cash equivalents, and marketable securities of $85.2 million, a decrease from $163.1 million in 2024, but expects funding to last into the second half of 2028 due to a recent $85 million private placement [6][23]. - Collaboration revenue increased to $6.4 million in 2025 from $2.3 million in 2024, attributed to a full year of collaboration with Novo Nordisk [7]. - Research and Development (R&D) expenses rose to $65.6 million in 2025 from $63.6 million in 2024, driven by increased costs related to KRRO-121 [8]. - General and Administrative (G&A) expenses decreased to $28.2 million in 2025 from $30.5 million in 2024, mainly due to lower professional fees [9]. - The net loss for 2025 was $117.3 million, compared to $83.6 million in 2024, primarily due to non-cash impairment charges [13][21]. Product Development - Korro nominated KRRO-121 as a development candidate for treating hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE), targeting a market opportunity exceeding $1 billion [4][5]. - KRRO-121 aims to stabilize glutamine synthase (GS) RNA, enhancing ammonia clearance in the liver and offering a more convenient subcutaneous delivery method compared to current therapies [5][16]. - The company is on track to nominate a development candidate for its GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency (AATD) in the second quarter of 2026 [4][11]. Strategic Initiatives - Korro hosted a virtual analyst day to discuss the unmet medical needs in hyperammonemia and the scientific rationale for KRRO-121 [11]. - The company is advancing its GalNAc-conjugated oligonucleotide program, achieving over 90% in vivo RNA editing, indicating high therapeutic potential [11]. - Upcoming milestones include regulatory filing for KRRO-121 in the second half of 2026 and the nomination of a third GalNAc-conjugated program [11].

Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this "Agreement") is made and entered into as of March 9, 2026 (the "Ef ective Date") by and among Korro Bio, Inc., a Delaware corporation (the "Company"), and each of the purchasers listed on the signature pages hereto, severally and not jointly (each a "Purchaser" and together the "Purchasers"). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 8 hereof. WHEREAS, the Company desires to sell to ...

Core Viewpoint - Korro Bio, Inc. has announced a private investment in public equity (PIPE) financing expected to generate approximately $85 million in gross proceeds, aimed at advancing its RNA editing platform and extending its cash runway into the second half of 2028 [1][4][9] Financing Details - The PIPE financing is led by Venrock Healthcare Capital Partners, with participation from both new and existing investors including ADAR1 Capital Management and New Enterprise Associates [2] - Korro is selling 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for 3,148,836 shares at $11.109 each, with an exercise price of $0.001 per share [3] Use of Proceeds - The net proceeds will support clinical development milestones for key pipeline assets, including KRRO-121 and the GalNAc-conjugated AATD program, and will also be used for working capital and general corporate purposes [4][9] - The funding will enable advancements in Korro's longevity and liver health program targeting the AMPKγ1 pathway [4] Company Overview - Korro Bio is focused on developing a new class of genetic medicines through RNA editing for both rare and prevalent diseases, utilizing its proprietary OPERA platform [8][10] - The company aims to enhance the precision and tunability of genetic medicines, potentially improving specificity and long-term tolerability [10]

Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases [2] - The company aims to create a portfolio of differentiated programs that utilize the body's natural RNA editing process, allowing for precise and transient single base edits [2] - By editing RNA instead of DNA, Korro seeks to enhance the precision and tunability of genetic medicines, potentially leading to increased specificity and improved long-term tolerability [2] Technology and Approach - Korro employs an oligonucleotide-based approach to deliver its medicines, leveraging its proprietary platform along with established delivery modalities and manufacturing expertise [2] - The company plans to utilize established regulatory pathways of approved oligonucleotide drugs to bring its medicines to patients [2] Upcoming Events - Ram Aiyar, Ph.D., the CEO and President of Korro, will present at the TD Cowen 46 Annual Health Care Conference in Boston, MA, on March 3, 2026, at 11:10 a.m. ET [1]

Core Insights - Korro Bio, Inc. is recognized as one of the best biotech stocks under $20, with significant potential for investment [1] Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing precision genetic medicines through RNA editing to address both rare and prevalent diseases [4] - The company utilizes its proprietary OPERA platform to advance RNA-editing therapies, which include both clinical and preclinical programs [4] Analyst Upgrades - H.C. Wainwright upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $20, emphasizing the independent value of KRRO-121 as a second risk-mitigated asset [2] - Chardan Capital also upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $15, citing strong preclinical data for KRRO-121 and indicating that the company has "turned the page" [3]

Core Insights - Korro Bio, Inc. (KRRO) shares increased by 13.9% to close at $13.31, with a notable 45.9% gain over the past four weeks, driven by strong trading volume [1][2] Company Developments - The rise in stock price is attributed to growing investor confidence in Korro's pipeline diversification, particularly with the introduction of KRRO-121 as a significant second asset alongside KRRO-110, an RNA-editing therapeutic candidate [2] - KRRO-121 is designed as a subcutaneously administered, GalNAc-conjugated RNA-editing therapy aimed at generating a de novo protein variant, with a first-in-human regulatory filing anticipated in the second half of 2026 [2] - Korro is also transitioning its AATD program to a GalNAc-conjugated construct, with a development candidate nomination expected in the first half of 2026, while advancing additional liver-targeted, subcutaneous GalNAc programs in cardiometabolic indications [2] Financial Expectations - The company is projected to report a quarterly loss of $1.86 per share, reflecting a year-over-year increase of 17.7%, with revenues expected to be $1.5 million, down 33.9% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Korro Bio, Inc. holds a Zacks Rank of 3 (Hold) within the Zacks Medical - Drugs industry, which includes other companies like BioCryst Pharmaceuticals (BCRX), that closed 0.2% higher at $6.67, but has seen a return of -14.6% over the past month [5] - BioCryst's consensus EPS estimate has decreased by 7.7% over the past month to $0.06, representing a year-over-year change of 146.2% [6]